{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:37:56Z","timestamp":1794512276197,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118227","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:14:10Z","timestamp":1760001250000},"page":"118227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Discovery of novel and potent NLRP3 inflammasome inhibitors with new lipophilic moieties"],"prefix":"10.1016","volume":"301","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1189-6433","authenticated-orcid":false,"given":"Hongzhu","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueya","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118227_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41586-022-05570-8","article-title":"Cryo-EM structures of the active NLRP3 inflammasome disc","volume":"613","author":"Xiao","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118227_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","article-title":"Drugging the NLRP3 inflammasome: from signaling mechanisms to therapeutic targets","volume":"23","author":"Vande Walle","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118227_bib3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41467-024-44990-0","article-title":"Pablo Pelegrin, Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1\u03b2 production","volume":"15","author":"Molina-L\u00f3pez","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118227_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.abb.2019.01.031","article-title":"The NLRP3 inflammasome-interleukin 1 pathway as a therapeutic target in gout","volume":"670","author":"Szekanecz","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2025.118227_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1124\/jpet.123.002013","article-title":"Reversal of high fat diet-induced obesity, systemic inflammation and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796","volume":"388","author":"Thornton","year":"2024","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118227_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2025.118227_bib7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1021\/acschemneuro.1c00831","article-title":"Novel small-molecule inhibitor of NLRP3 inflammasome reverses cognitive impairment in an Alzheimer's disease model","volume":"13","author":"Haseeb","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118227_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12974-023-02830-w","article-title":"Pharmacologic inhibition of NLRP3 reduces the levels of \u03b1-synuclein and protects dopaminergic neurons in a model of Parkinson's disease","volume":"20","author":"Amo-Aparicio","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2025.118227_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116581","article-title":"Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD immunotherapy","volume":"275","author":"Yin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib10","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1021\/acs.jmedchem.3c02407","article-title":"Discovery and development of NLRP3 inhibitors targeting the LRR domain to disrupt NLRP3-NEK7 interaction for the treatment of rheumatoid arthritis","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41584-022-00797-1","article-title":"IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting","volume":"18","author":"Broderick","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2025.118227_bib12","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118227_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118227_bib14","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.3390\/molecules25235533","article-title":"Inhibiting the NLRP3 inflammasome","volume":"25","author":"El-Sharkawy","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118227_bib15","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1021\/acs.jmedchem.2c01250","article-title":"Overcoming preclinical safety obstacles to discover (S)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): a potent and selective NLRP3 inhibitor","volume":"65","author":"McBride","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1471","article-title":"A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis","volume":"13","author":"Klughammer","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118227_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.1318","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of ZY-IL1 in three patients with cryopyrin-associated periodic syndromes","volume":"13","author":"Hissaria","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2025.118227_bib18","doi-asserted-by":"crossref","first-page":"14897","DOI":"10.1021\/acs.jmedchem.3c01398","article-title":"Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders","volume":"66","author":"Harrison","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1124\/jpet.123.001941","article-title":"Open access target cell activation of a structurally novel NOD-like receptor pyrin domain-containing protein 3 inhibitor NT-0796 enhances potency","volume":"388","author":"Smolak","year":"2024","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118227_bib20","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1021\/acs.jmedchem.4c02759","article-title":"Discovery of DFV890, a potent sulfonimidamide-containing NLRP3 inflammasome inhibitor","volume":"68","author":"Shen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib21","doi-asserted-by":"crossref","first-page":"20780","DOI":"10.1021\/acs.jmedchem.4c02350","article-title":"Discovery of NP3-253, a potent brain penetrant inhibitor of the NLRP3 inflammasome","volume":"67","author":"Mackay","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib22","doi-asserted-by":"crossref","first-page":"14195","DOI":"10.1021\/acs.jmedchem.5c00781","article-title":"Discovery of AZD4144, a selective and potent NLRP3 inhibitor for the treatment of inflammatory diseases","volume":"68","author":"Johansson","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib23","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acs.jmedchem.3c02098","article-title":"Discovery of potent, orally bioavailable, tricyclic NLRP3 inhibitors","volume":"67","author":"Velcicky","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41586-022-04467-w","article-title":"Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3","volume":"604","author":"Hochheiser","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118227_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","article-title":"Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization","volume":"6","author":"Okamoto","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118227_bib26","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1021\/acs.jmedchem.6b00472","article-title":"The \u201ccyclopropyl fragment\u201d is a versatile player that frequently appears in preclinical\/clinical drug molecules","volume":"59","author":"Talele","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/jm960673l","article-title":"Sulfonimidamide analogs of oncolytic sulfonylureas","volume":"40","author":"Toth","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib28","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.1021\/acsomega.2c00125","article-title":"Structure\u2013stability relationship of NLRP3 inflammasome-inhibiting sulfonylureas","volume":"7","author":"Keuler","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.118227_bib29","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1021\/jm00050a018","article-title":"Latent alkyl isocyanates as inhibitors of aldehyde dehydrogenase in vivo","volume":"37","author":"Nagasawa","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1021\/jm00126a032","article-title":"N1-alkyl-substituted derivatives of chlorpropamide as inhibitors of aldehyde dehydrogenase","volume":"32","author":"Nagasawa","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib31","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118227_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bcpt.12992","article-title":"Interaction of sulfonylureas with liver uptake transporters OATP1B1 and OATP1B3","volume":"123","author":"Chen","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118227_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1021\/op0340659","article-title":"Design of new reaction conditions for the Sugasawa reaction based on mechanistic insights","volume":"7","author":"Prasad","year":"2003","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2025.118227_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0022-328X(95)05819-B","article-title":"BINAP-Ru(II) and BINAP-Rh(I)-catalyzed asymmetric hydrogenation of olefins without heteroatom-functionalities","volume":"502","author":"Ohta","year":"1995","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2025.118227_bib35","doi-asserted-by":"crossref","first-page":"14937","DOI":"10.1002\/anie.201708590","article-title":"One-pot, three-component sulfonimidamide synthesis exploiting the sulfinylamine reagent N-sulfinyltritylamine, TrNSO","volume":"56","author":"Davies","year":"2017","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejmech.2025.118227_bib36","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1039\/C4RA14056G","article-title":"A convenient synthetic route to sulfonimidamides from sulfonamides","volume":"5","author":"Chen","year":"2015","journal-title":"RSC Adv."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T08:00:33Z","timestamp":1762675233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S0223523425009924"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118227","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel and potent NLRP3 inflammasome inhibitors with new lipophilic moieties","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118227"}}